409 related articles for article (PubMed ID: 11739740)
1. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
Esparís-Ogando A; Díaz-Rodríguez E; Montero JC; Yuste L; Crespo P; Pandiella A
Mol Cell Biol; 2002 Jan; 22(1):270-85. PubMed ID: 11739740
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
4. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
Yuste L; Montero JC; Esparís-Ogando A; Pandiella A
Cancer Res; 2005 Aug; 65(15):6801-10. PubMed ID: 16061662
[TBL] [Abstract][Full Text] [Related]
5. Neuregulin induces sustained reactive oxygen species generation to mediate neuronal differentiation.
Goldsmit Y; Erlich S; Pinkas-Kramarski R
Cell Mol Neurobiol; 2001 Dec; 21(6):753-69. PubMed ID: 12043846
[TBL] [Abstract][Full Text] [Related]
6. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
7. Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells.
Nguyen HT; Adam RM; Bride SH; Park JM; Peters CA; Freeman MR
Am J Physiol Cell Physiol; 2000 Oct; 279(4):C1155-67. PubMed ID: 11003596
[TBL] [Abstract][Full Text] [Related]
8. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
Frohnert PW; Stonecypher MS; Carroll SL
Glia; 2003 Aug; 43(2):104-18. PubMed ID: 12838503
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line.
Fallon KB; Havlioglu N; Hamilton LH; Cheng TP; Carroll SL
J Neurooncol; 2004 Feb; 66(3):273-84. PubMed ID: 15015657
[TBL] [Abstract][Full Text] [Related]
11. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.
Berger MB; Mendrola JM; Lemmon MA
FEBS Lett; 2004 Jul; 569(1-3):332-6. PubMed ID: 15225657
[TBL] [Abstract][Full Text] [Related]
12. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells.
Egeblad M; Jäättelä M
Int J Cancer; 2000 Jun; 86(5):617-25. PubMed ID: 10797281
[TBL] [Abstract][Full Text] [Related]
13. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway.
Mody N; Leitch J; Armstrong C; Dixon J; Cohen P
FEBS Lett; 2001 Jul; 502(1-2):21-4. PubMed ID: 11478941
[TBL] [Abstract][Full Text] [Related]
14. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Daly JM; Olayioye MA; Wong AM; Neve R; Lane HA; Maurer FG; Hynes NE
Oncogene; 1999 Jun; 18(23):3440-51. PubMed ID: 10376522
[TBL] [Abstract][Full Text] [Related]
15. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
16. Expression, localization, and regulation of the neuregulin receptor ErbB3 in mouse heart.
Campreciós G; Lorita J; Pardina E; Peinado-Onsurbe J; Soley M; Ramírez I
J Cell Physiol; 2011 Feb; 226(2):450-5. PubMed ID: 20672328
[TBL] [Abstract][Full Text] [Related]
17. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis.
Kainulainen V; Sundvall M; Määttä JA; Santiestevan E; Klagsbrun M; Elenius K
J Biol Chem; 2000 Mar; 275(12):8641-9. PubMed ID: 10722704
[TBL] [Abstract][Full Text] [Related]
18. The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.
Centa A; Rodríguez-Barrueco R; Montero JC; Pandiella A
Mol Oncol; 2018 Jun; 12(7):1061-1076. PubMed ID: 29683256
[TBL] [Abstract][Full Text] [Related]
19. Chimeric receptor analyses of the interactions of the ectodomains of ErbB-1 with epidermal growth factor and of those of ErbB-4 with neuregulin.
Kim JH; Saito K; Yokoyama S
Eur J Biochem; 2002 May; 269(9):2323-9. PubMed ID: 11985614
[TBL] [Abstract][Full Text] [Related]
20. The neuregulin-I/ErbB signaling system in development and disease.
Britsch S
Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
